The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

The final draft guidance recommends Sanofi's Praluent (alirocumab) and Amgen's Repatha (evolocumab) for adults with primary hypercholesterolaemia or mixed dyslipidaemia to help reduce risk of ...

Repatha (evolocumab) is a brand-name subcutaneous injection that isn’t known to interact with alcohol, other drugs, or supplements. However, Repatha has health-related interactions that are ...

[Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab (Repatha, Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015.

Among these PCSK9-targeting therapies is Novartis’s Leqvio (inclisiran), Amgen’s Repatha (evolocumab), and Regeneron’s Praluent (alirocumab). However, none of these therapies offer the single-dose ...